Artelo Biosciences, Inc. ARTL
2.22 USD +0.05 (+2.30%)
Nov 3, 2026, 3:20 PM EST
2.12 Day range 2.22
2.05 52-week range 179.19
- YTD
- -93.26%
- 1 year
- -97.26%
News
benzinga.com Artelo Biosciences To Present Data For Its ART27.13 To Treat Chemotherapy-Induced Neuropathic Pain At IASP 2026 World Congress On Pain Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with
globenewswire.com Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain Nonclinical studies demonstrated reductions in two key measures of neuropathic pain Ongoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13's potential to address multiple…
benzinga.com Artelo Bioscience To Present Data On ART26.12 Program At IASP 2026 World Congress On Pain, October 26–30; Growing Body Of Data Supports ART26.12’s Potential As A Novel, Non-Opioid Treatment For Pain Ahead Of Planned Multiple Ascending Dose Study Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with
globenewswire.com Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world's largest gathering of pain professionals
defenseworld.net Artelo Biosciences, Inc. (NASDAQ:ARTL) Stock Short Interest Rises 104.7% Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 46,160 shares, a…
globenewswire.com Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications
defenseworld.net Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Shorted: Short Interest Down 37.2% in September Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 22,550 shares,…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Firefly Neuroscience (NASDAQ:AIFF) shares increased by 33.2% to $1.58 during Friday's regular session. The company's market cap stands at $18.6 million. Apimeds Pharmaceuticals (AMEX:APUS)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen…
benzinga.com Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000 U.S. stocks fell Thursday as tech slid; jobless claims beat estimates. Oil rose, while APUS surged 245% and BENF plunged 33%.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to…
benzinga.com Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines…
benzinga.com Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening? Artelo Biosciences, Inc. (NASDAQ: ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics…
benzinga.com Artelo Biosciences Files Provisional Patent Application For ART27.13 As Monotherapy And In Combination With GLP-1 Receptor Agonists As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeksApplication…
globenewswire.com Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares…
benzinga.com Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug Artelo Biosciences shares new nonclinical data showing its oral cannabinoid drug ART27.13 matches semaglutide weight loss in obese mice.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved…
globenewswire.com Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic ® and Wegovy ®
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market session. The company's market cap stands at $8.9 million. Akanda (NASDAQ:AKAN) shares increased by 27.52% to…
defenseworld.net Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 36.9% in August Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 85,320 shares, a…
benzinga.com Artelo Biosciences Announces 1-For-9 Reverse Stock Split, Effective August 31 Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with
globenewswire.com Artelo Biosciences Announces Reverse Stock Split Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
benzinga.com Artelo Biosciences Issued Notification Of Allowance From Japanese Patent Office With Decision To Grant Patent Application For Commercial Formulation Of ART27.13 Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living…
globenewswire.com Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating…
benzinga.com Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies The Patent Claims are for the Intended Commercial Formulation of ART27.13Expected to Extend Patent Protection for ART27.13 through 2041SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo…
globenewswire.com Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo…- benzinga.com Artelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.89) per share. This is a 94.71 percent increase over losses of $(16.83) per share from the same period last year.
globenewswire.com Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating…
benzinga.com Artelo Biosciences Says First Patient Dosed In DREAM Study Evaluating Effects Of ART27.13 In Patients With Glaucoma Or Ocular Hypertension; Initial DREAM Study Results Anticipated In Q4 Investigator-led study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmologyInitial DREAM Study Results Anticipated in Q4 2026SOLANA BEACH, Calif.,…
benzinga.com Artelo Biosciences Announces Publication Of Article 'Evaluating The Pharmacokinetics, Efficacy, And Safety Of Low Dose Cannabidiol' In The British Journal Of Clinical Pharmacology The peer-reviewed evaluation analyzed the efficacy, pharmacokinetics, and safety data obtained from over 50 studies using low-dose cannabidiol (CBD) commonly found in over-the-counter products — and…- benzinga.com Artelo Biosciences Announces Oral Administration Of ART26.12 Lowers Osteoarthritis-Associated Pain Behaviors Over 4-Week Testing; Shows Efficacy To Naproxen Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living…
globenewswire.com Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Management Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market session. The market value of their outstanding shares is at $2.6 million. China Pharma Holding (AMEX:CPHI)…
globenewswire.com Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote Every proxy submitted helps establish the quorum needed…- benzinga.com Artelo Biosciences Reports Preclinical Results For ART27.13 in Cancer-Related Neuropathic Pain; Findings Suggest Broader Utility In Cancer Supportive Care, Building On Interim Findings From CAReS Phase 2 Clinical Study Which Demonstrated Improvements In Body Weight, Lean Body Mass And Activity Levels Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancerFindings suggest broader utility in cancer supportive care,…
globenewswire.com Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care,…- benzinga.com Artelo Biosciences Announces Data From Preclinical Trial In Neuropathic Pain From Spinal Cord Injury Shows Lowered Mechanical Hypersensitivity Associated With Nerve Injury; Decreased Spontaneous Pain-Related Behaviors Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with
globenewswire.com Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain The nonclinical study conducted at Stony Brook…- benzinga.com Artelo Biosciences Identifies Lipid Pathway Link For ART26.12 In Multi-Omics Cancer Research Presentation At The CRS 2026 Annual Symposium Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain,…
globenewswire.com Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12 Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by…- benzinga.com Artelo Biosciences Announces Two Presentations Supporting Development Of ART26.12, Its Selective Fatty Acid Binding Protein 5 Inhibitor The presentations include results from the Phase 1 clinical study of ART26.12 as well as new biomarker analyses designed to identify indicators of target engagement and pharmacological activity in…
globenewswire.com Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29, 2026…- benzinga.com Artelo Biosciences Presents Metabolite Identification And Profiling Data From Its FABP Inhibitor Candidate ART26.12; Tracks Three Metabolites From Plasma Of Healthy Volunteers Given Single 900 Mg Oral Dose Of ART26.12 Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with…
globenewswire.com Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success Artelo's lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London Artelo's lead medicinal chemist reveals findings at the Royal…
benzinga.com Crude Oil Falls Over 5%; Dycom Industries Shares Surge Following Q1 Results U.S. stocks traded mixed, Nasdaq down 0.3%. Dow up 0.59%, S&P 500 down 0.09%. Consumer discretionary shares up 1.9%. Dycom Industries reports strong earnings.
benzinga.com Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results US stocks mixed, Dow up 300 pts. Dow up 0.64%, NASDAQ down 0.34%. Consumer discretionary up 1.7%, energy down 1.9%. DKS stock falls 5% on mixed results.
benzinga.com Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares rose 7% in pre-market trading as Q2 guidance exceeded expectations.